About Prexa

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinsons disease.

Prexas proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles.

Synthesis Capital, formerly Advent Healthcare Ventures, is a co-founder of Prexa Pharmaceuticals and provided the company’s Series A financing which closed in 2006. The Series B financing was led by Advent Healthcare Ventures with participation from Shire Pharmaceuticals and closed in April 2011.